H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit ...

Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has ...

In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other growth stocks. The market closed last week mostly lower, however ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...